Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE) (2022) Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, et al. Journal article PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients (2022) Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, et al. Journal article EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy (2022) Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn BV, Barinoff J, et al. Journal article Sex-specific association between prenatal androgenization (second-to-fourth digit length ratio) and frontal brain volumes in adolescents (2022) Lenz B, Gerhardt S, Boroumand-Jazi R, Eichler A, Buchholz VN, Fasching P, Kornhuber J, et al. Journal article Machine Learning-based Detection of In-Utero Fetal Presentation from Non-Invasive Fetal ECG (2022) Jäger K, Nissen M, Richer R, Rahm S, Titzmann A, Fasching P, Eskofier B, Leutheuser H Conference contribution, Conference Contribution Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2 (2022) Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, et al. Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Expression of disialoganglioside GD2 in breast cancer subtypes (2022) Gaß P, Kailayangiri S, Hübner H, Rübner M, Hartmann A, Häberle L, Völkl S, et al. Conference contribution Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution